Research could help improve early diagnosis of prostate cancer

February 25, 2014, University of Essex

Prostate cancer patients could get better diagnosis and treatment for the disease in the future thanks to a successful research project at the University of Essex.

Currently, is it difficult to distinguish between benign and aggressive malignant tumours, meaning some prostate cancer patients are unnecessarily "over-treated" which can lead to needless distress and anxiety.

Scientists in this field have been looking to find biomarkers to distinguish between the two types of tumours, and now prostate cancer experts at Essex have found an important link between the molecule known as BORIS and malignant tumours.

The research, published in the February issue of the journal Prostate, could lead the way for pathologists to have better tools for the early diagnosis of prostate cancer and for patients to get the most appropriate level of treatment for them.

The major three-year study involved the University-based Essex Biomedical Sciences Institute (EBSI) working with the Colchester Catalyst Charity and the Urology and Pathology Departments at Colchester Hospital University NHS Foundation Trust.

Leading the project at Essex was Professor Elena Klenova, who was part of the scientific team which first discovered BORIS in 2002 and its importance in prostate cancer research.

"Apart from playing an important role in the development of sperm in men, BORIS is not usually expressed in the body," explained Professor Klenova, "However, it does appear in malignant tumours, which is why it is seen as an important molecule in the development of cancer. It also can help distinguish between normal and cancerous cells".

Prostate cancer is the most common type of cancer in men. Around 37,000 UK men are diagnosed with the disease each year. Many develop very slowly, but in a small proportion of cases the cancer grows more quickly and spreads to other areas of the body, sometimes proving fatal.

The research was co- funded by the Colchester Catalyst Charity as part of its ongoing mission to improve the health care of people living in north-east Essex. However, the study's findings obviously have a wider impact generally for the treatment and the understanding of prostate cancer.

Professor Klenova's team at Essex, which included Zubair Cheema and Yukti Hari-Gupta, sponsored by Colchester Hospital University NHS Foundation Trust and the Colchester Catalyst Charity, respectively, looked at levels of BORIS in benign and malignant tumours and found that it was only present in malignant tumours, suggesting that the molecule could prove to be a useful biomarker for aggressive symptoms of the disease.

John Corr, consultant urological surgeon at Colchester Hospital University NHS Foundation Trust, said: "Collaborative work like this between a university and an acute hospital trust is a very under-utilised resource in the NHS, and I am very happy to be involved in it.

"This is a very exciting finding and will help in our daily fight against prostate cancer.

"It may more accurately identify those patients that need active treatment and aid in predicting long-term outcomes."

The scientists will now investigate the link between BORIS and malignant tumours further with a bigger study.

Explore further: Scientists finally discover which prostate cancers are life-threatening

Related Stories

Scientists finally discover which prostate cancers are life-threatening

November 19, 2013
Cancer Research UK scientists have discovered that the presence of a specific protein can distinguish between prostate cancers that are aggressive and need further treatment from those that may never seriously harm the patient.

Genetic screening can identify men with advanced prostate cancer

February 20, 2014
Screening men with a family history of prostate cancer for a range of gene mutations can identify those who are at high risk of aggressive forms of the disease and in need of lifelong monitoring, a new study has shown.

Scientists overcome barrier to prostate cancer research

October 24, 2013
Monash scientists have overcome one of the major barriers to the study and treatment of localised -or organ confined- prostate cancer.

New imaging agent has an appetite for dangerous prostate tumors

December 8, 2011
Non-invasive imaging detects prostate cancer earlier than ever before, but can't accurately distinguish between malignant and benign disease. According to Lawson Health Research Institute's Drs. John Lewis and Len Luyt, a ...

Prostate cancer advance could improve treatment options

February 12, 2014
Researchers at the University of East Anglia have made an important advance in understanding genetic changes associated with terminal prostate cancer.

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.